Two International Drug Developers Award $2.5 Million in Thorough QT Studies to eResearchTechnology
12 April 2005 - 12:05AM
PR Newswire (US)
Two International Drug Developers Award $2.5 Million in Thorough QT
Studies to eResearchTechnology Agreements with Europe-based and
Japan-based Pharmaceutical Organizations Continue Trend Toward
Implementation of Regulatory Guidance by International
Organizations PHILADELPHIA, April 11 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT), (NASDAQ:ERES), a leading provider
of centralized electrocardiographic (ECG) collection and
interpretation services, announced today that it has been awarded
two Thorough QT studies valued at more than $2.5 million in cardiac
safety monitoring and services from a Europe-based top 50 global
pharmaceutical and an expanding Japan-based international drug
developer for two compounds in clinical trials. The awards cover
two significant Thorough QT studies, for which eRT is providing
comprehensive support, including provision of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data
that is subsequently provided to eRT for analysis. eRT will perform
digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. "Following by several
weeks news of Thorough QT Study agreements from another Japan-based
drug developer and the initial study from the same top 50
Europe-based pharmaceutical referenced in this announcement, these
contracts illustrate the growing trend toward implementation of
regulatory guidance worldwide," said Scott Grisanti, senior vice
president of business development and chief marketing officer at
eRT. "Whether an emerging growth organization or a top 50
pharmaceutical, drug developers whose primary presence is outside
the U.S. are increasingly turning to eRT to provide critical
services for Thorough QT studies. eRT's ability to leverage partner
agreements with Clinical Pharmacology Units here and abroad, along
with our capability to provide varying levels of consultation and
the capacity to conduct studies in the U.S. and abroad, provide the
flexibility and expertise required for such organizations to
successfully complete these mission critical projects." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The
sponsors may cancel these agreements at their sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Report on Form 10-K filed with the Securities and
Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT:
Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-858-704-5065, for
eResearchTechnology, Inc. Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles